Literature DB >> 19666477

HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity.

Barbara Müller1, Maria Anders, Hisashi Akiyama, Sonja Welsch, Bärbel Glass, Krisztina Nikovics, Francois Clavel, Hanna-Mari Tervo, Oliver T Keppler, Hans-Georg Kräusslich.   

Abstract

Protease inhibitors (PI) act by blocking human immunodeficiency virus (HIV) polyprotein processing, but there is no direct quantitative correlation between the degree of impairment of Gag processing and virion infectivity at low PI concentrations. To analyze the consequences of partial processing, virus particles were produced in the presence of limiting PI concentrations or by co-transfection of wild-type proviral plasmids with constructs carrying mutations in one or more cleavage sites. Low PI concentrations caused subtle changes in polyprotein processing associated with a pronounced reduction of particle infectivity. Dissection of individual stages of viral entry indicated a block in accumulation of reverse transcriptase products, whereas virus entry, enzymatic reverse transcriptase activity, and replication steps following reverse transcription were not affected. Co-expression of low amounts of partially processed forms of Gag together with wild-type HIV generally exerted a trans-dominant effect, which was most prominent for a construct carrying mutations at both cleavage sites flanking the CA domain. Interestingly, co-expression of low amounts of Gag mutated at the CA-SP1 cleavage site also affected processing activity at this site in the wild-type virus. The results indicate that low amounts (<5%) of Gag processing intermediates can display a trans-dominant effect on HIV particle maturation, with the maturation cleavage between CA and SP1 being of particular importance. These effects are likely to be important for the strong activity of PI at concentrations achieved in vivo and also bear relevance for the mechanism of action of the antiviral drug bevirimat.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19666477      PMCID: PMC2785601          DOI: 10.1074/jbc.M109.027144

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

1.  Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies.

Authors:  E Race; E Dam; V Obry; S Paulous; F Clavel
Journal:  AIDS       Date:  1999-10-22       Impact factor: 4.177

2.  Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells.

Authors:  S Tang; T Murakami; B E Agresta; S Campbell; E O Freed; J G Levin
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

3.  A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes.

Authors:  Marielle Cavrois; Carlos De Noronha; Warner C Greene
Journal:  Nat Biotechnol       Date:  2002-09-30       Impact factor: 54.908

4.  The stoichiometry of Gag protein in HIV-1.

Authors:  John A G Briggs; Martha N Simon; Ingolf Gross; Hans-Georg Kräusslich; Stephen D Fuller; Volker M Vogt; Marc C Johnson
Journal:  Nat Struct Mol Biol       Date:  2004-06-20       Impact factor: 15.369

5.  Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication.

Authors:  Brett M Forshey; Uta von Schwedler; Wesley I Sundquist; Christopher Aiken
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

6.  Isolation of human immunodeficiency virus type 1 cores: retention of Vpr in the absence of p6(gag).

Authors:  M A Accola; A Ohagen; H G Göttlinger
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

7.  Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

Authors:  Xiping Wei; Julie M Decker; Hongmei Liu; Zee Zhang; Ramin B Arani; J Michael Kilby; Michael S Saag; Xiaoyun Wu; George M Shaw; John C Kappes
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

8.  Evidence for a stable interaction of gp41 with Pr55(Gag) in immature human immunodeficiency virus type 1 particles.

Authors:  D J Wyma; A Kotov; C Aiken
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

9.  Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease.

Authors:  Steve C Pettit; Gavin J Henderson; Celia A Schiffer; Ronald Swanstrom
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 N-terminal capsid mutants containing cores with abnormally high levels of capsid protein and virtually no reverse transcriptase.

Authors:  Shixing Tang; Tsutomu Murakami; Naiqian Cheng; Alasdair C Steven; Eric O Freed; Judith G Levin
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

View more
  67 in total

1.  Electron cryotomography studies of maturing HIV-1 particles reveal the assembly pathway of the viral core.

Authors:  Cora L Woodward; Sarah N Cheng; Grant J Jensen
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

Review 2.  Features, processing states, and heterologous protein interactions in the modulation of the retroviral nucleocapsid protein function.

Authors:  Gilles Mirambeau; Sébastien Lyonnais; Robert J Gorelick
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

3.  Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity.

Authors:  Chris M Parry; Madhavi Kolli; Richard E Myers; Patricia A Cane; Celia Schiffer; Deenan Pillay
Journal:  Antimicrob Agents Chemother       Date:  2010-12-13       Impact factor: 5.191

4.  The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation.

Authors:  Mary Ann Checkley; Benjamin G Luttge; Ferri Soheilian; Kunio Nagashima; Eric O Freed
Journal:  Virology       Date:  2010-02-20       Impact factor: 3.616

5.  Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance.

Authors:  S Alireza Rabi; Gregory M Laird; Christine M Durand; Sarah Laskey; Liang Shan; Justin R Bailey; Stanley Chioma; Richard D Moore; Robert F Siliciano
Journal:  J Clin Invest       Date:  2013-08-27       Impact factor: 14.808

6.  Selection of fully processed HIV-1 nucleocapsid protein is required for optimal nucleic acid chaperone activity in reverse transcription.

Authors:  Tiyun Wu; Robert J Gorelick; Judith G Levin
Journal:  Virus Res       Date:  2014-06-20       Impact factor: 3.303

7.  RNA and Nucleocapsid Are Dispensable for Mature HIV-1 Capsid Assembly.

Authors:  Simone Mattei; Annica Flemming; Maria Anders-Össwein; Hans-Georg Kräusslich; John A G Briggs; Barbara Müller
Journal:  J Virol       Date:  2015-07-15       Impact factor: 5.103

Review 8.  HIV type 1 Gag as a target for antiviral therapy.

Authors:  Abdul A Waheed; Eric O Freed
Journal:  AIDS Res Hum Retroviruses       Date:  2011-09-21       Impact factor: 2.205

9.  Distinct nucleic acid interaction properties of HIV-1 nucleocapsid protein precursor NCp15 explain reduced viral infectivity.

Authors:  Wei Wang; Nada Naiyer; Mithun Mitra; Jialin Li; Mark C Williams; Ioulia Rouzina; Robert J Gorelick; Zhengrong Wu; Karin Musier-Forsyth
Journal:  Nucleic Acids Res       Date:  2014-05-09       Impact factor: 16.971

10.  Novel dengue virus NS2B/NS3 protease inhibitors.

Authors:  Hongmei Wu; Stefanie Bock; Mariya Snitko; Thilo Berger; Thomas Weidner; Steven Holloway; Manuel Kanitz; Wibke E Diederich; Holger Steuber; Christof Walter; Daniela Hofmann; Benedikt Weißbrich; Ralf Spannaus; Eliana G Acosta; Ralf Bartenschlager; Bernd Engels; Tanja Schirmeister; Jochen Bodem
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.